We recognise and consider the meta and meso-trends that shape and threaten our world.
There is increased regulatory scrutiny of companies’ non-financial commitments and performance in areas such as climate change, human rights, tax practices, and diversity and inclusion. Shareholders and other stakeholders are demanding that companies exceed compliance and publicly account for their impacts on people and the planet.
Demographic and epidemiological trends are changing as the global population is expected to rise to 10 billion people by 2050, with the proportion of over 60s expected to reach over 20%, up from 12% in 2015. The increased prevalence of chronic diseases and the focus by governments on improving equitable access have been brought into sharp relief by the COVID-19 pandemic.
The rise of new technologies is transforming the speed, power and location of work and research processes and poses an increased cyber security threat.
Companies are expected to play a role in reducing their emissions and report on these. Changing disease patterns and extreme weather events may present risks to our people and supply chains, while the potential economic and geopolitical consequences of climate change may alter our commercial environment.
Increased focus on diversity and inclusion has become a global imperative, particularly in the face of greater polarisation, divisions and inequity in our society. Not only is this a moral imperative, but there is clear recognition that companies that are more diverse and inclusive, are more successful and sustainable.
Rapidly changing needs and imperatives in healthcare research resulted in increased funding for biomedical research and translational medicine, including significant expansion and prioritisation of R&D in China. There is a growing significance of proteomics, as well as a focus on increased research reproducibility to reduce wasted time and resources.
Ensuring the consistency and quality of our products.
Pre-empting and meeting future research needs, building an effective R&D model and continuing Abcam’s differentiation in product and service.
Ensuring that our products are appropriately used for the purposes they are intended and that suppliers adhere to rigorous standards of animal welfare and actively promote the adoption of the NC3R’s directive.
Investing in our most valuable asset, our human capital.
Growing a diverse team and inclusive culture.
Attracting, developing and retaining talent so that we can grow and thrive.
Providing a healthy, safe, and enriching environment.
Supporting the next generation of scientists by encouraging a diverse pipeline of talent to enter into science.
Developing and maintaining strong, mutually-beneficial and long-term partnership network.
Preventing the loss of control of key data or IP.
Ensuring that Abcam’s global supply chain is ethically responsible, adheres to the same high standards of conduct and is validated.
Reducing greenhouse gas (GHG) emissions. Reducing carbon emissions and developing a roadmap to Net Zero.
Reducing waste throughout the value chain.
Ensuring compliance with all environmental legislation and regulation wherever we operate.
Monitor and reduce the risk of cyber-attacks.
Ensuring a zero tolerance of bribery and corruption anywhere in our value chain and that our code of conduct is upheld across our business.
Our impacts and the progress we make and the measures we take to meet them are dynamic and ongoing.
Our sustainability framework weaves together our purpose, culture and strategy, and sets out our priority areas.
It is for everyone in the business to play their part: from our Board of Directors through to all of our employees.